Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Aggressive B-Cell Malignancies”

96 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 96 results

Testing effectiveness (Phase 2)Looking for participantsNCT06534437
What this trial is testing

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Ryvu Therapeutics SA 178
Large-scale testing (Phase 3)Study completedNCT02910063
What this trial is testing

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

Who this might be right for
B-Cell Non Hodgkin Lymphoma
Amgen 41
Early research (Phase 1)Study completedNCT02303392
What this trial is testing

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Prolymphocytic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Mantle Cell Lymphoma+2 more
Jennifer Woyach 34
Testing effectiveness (Phase 2)Ended earlyNCT05588440
What this trial is testing

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Relapsed/Refractory Aggressive B-Cell Malignancies
Oncternal Therapeutics, Inc 9
Testing effectiveness (Phase 2)Study completedNCT00086944
What this trial is testing

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Study completedNCT03458260
What this trial is testing

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Who this might be right for
Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation 74
Testing effectiveness (Phase 2)Study completedNCT03210662
What this trial is testing

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent Aggressive Non-Hodgkin LymphomaRecurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma+8 more
M.D. Anderson Cancer Center 17
Early research (Phase 1)Looking for participantsNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Early research (Phase 1)Active Not RecruitingNCT01840566
What this trial is testing

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Large-scale testing (Phase 3)Study completedNCT00078949
What this trial is testing

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
NCIC Clinical Trials Group 849
Testing effectiveness (Phase 2)Active Not RecruitingNCT03625037
What this trial is testing

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Who this might be right for
DLBCLHigh-grade B-cell Lymphoma (HGBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+6 more
Genmab 666
Testing effectiveness (Phase 2)Study completedNCT02271945
What this trial is testing

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Who this might be right for
Relapsed/Refractory Aggressive B-cell Lymphomas
MedImmune LLC 10
Testing effectiveness (Phase 2)Study completedNCT00006383
What this trial is testing

Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Inex Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT00385125
What this trial is testing

Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL

Who this might be right for
Lymphoma, High-Grade
University of Magdeburg 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197307
What this trial is testing

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3B
Universität Münster 120
Testing effectiveness (Phase 2)WithdrawnNCT04882163
What this trial is testing

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Celgene
Testing effectiveness (Phase 2)Study completedNCT00244985
What this trial is testing

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Roswell Park Cancer Institute 42
Early research (Phase 1)Study completedNCT03003546
What this trial is testing

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic Lymphoma+3 more
Mayo Clinic 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT02436707
What this trial is testing

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Who this might be right for
Lymphoma
Canadian Cancer Trials Group 129
Load More Results